Luspatercept刺激输血依赖型地中海贫血患者的红细胞生成、增加铁利用并重新分布体内铁
BELIEVE试验(NCT02604433)纳入336例输血依赖型地中海贫血成人,分析luspatercept治疗后的生物标志物变化。输血铁负荷速率降低20%(约1.4 g,约7单位血;中位铁负荷速率差:-0.05 ± 0.07 mg Fe/kg/天,p< .0001),血清铁蛋白降低19.2%(269.3 ± 963.7 μg/L,p< .0001),但肝铁含量未降低(从5.3增至6.7 mg/g dw,无统计学显著性)。红细胞生成标志物升高、铁调素降低,提示铁从巨噬细胞向肝细胞重新分布,需联合螯合剂管理铁。
要点
- BELIEVE试验中luspatercept使输血铁负荷速率降低20%(约7单位血),血清铁蛋白降低19.2%。
- 肝铁含量未降低,从5.3增至6.7 mg/g dw(无统计学显著性),脾完整者肝铁增加。
- 红细胞生成标志物升高(sTfR1升66%、网织红细胞升112%),铁调素降53%, erythroferrone升51%。
核心结论
- Luspatercept在输血依赖型地中海贫血中降低输血依赖,可能将铁从巨噬细胞重新分布至肝细胞,需联合螯合剂覆盖以有效管理铁。
研究设计与样本
- BELIEVE试验(NCT02604433)纳入336例输血依赖型地中海贫血成人的生物标志物分析。
主要发现
- 输血铁负荷速率降低20%(约1.4 g,约7单位血;中位铁负荷速率差:-0.05 ± 0.07 mg Fe/kg/天,p< .0001)。
- 血清铁蛋白降低19.2%(269.3 ± 963.7 μg/L,p< .0001)。
- 肝铁含量未降低,从5.3增至6.7 mg/g dw(无统计学显著性);脾完整者肝铁增加。
- 促红细胞生成素升高93%、生长分化因子15升高59%、可溶性转铁蛋白受体1升高66%、网织红细胞升高112%、 erythroferrone升高51%、铁调素降低53%(均p< .0001)。
临床怎么用
- 作者认为,luspatercept治疗中红细胞生成和铁调素变化降低输血依赖,并可能将铁从巨噬细胞重新分布至肝细胞,需联合螯合剂覆盖以有效管理铁。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Luspatercept, a ligand-trapping fusion protein, binds select TGF-β superfamily ligands implicated in thalassemic erythropoiesis, promoting late-stage erythroid maturation. Luspatercept reduced transfusion burden in the BELIEVE trial (NCT02604433) of 336 adults with transfusion-dependent thalassemia (TDT). Analysis of biomarkers in BELIEVE offers novel physiological and clinical insights into benefits offered by luspatercept. Transfusion iron loading rates decreased 20% by 1.4 g (~7 blood units; median iron loading rate difference: -0.05 ± 0.07 mg Fe/kg/day, p< .0001) and serum ferritin (s-ferritin) decreased 19.2% by 269.3 ± 963.7 μg/L (p < .0001), indicating reduced macrophage iron. However, liver iron content (LIC) did not decrease but showed statistically nonsignificant increases from 5.3 to 6.7 mg/g dw. Erythropoietin, growth differentiation factor 15, soluble transferrin receptor 1 (sTfR1), and reticulocytes rose by 93%, 59%, 66%, and 112%, respectively; accordingly, erythroferrone increased by 51% and hepcidin decreased by 53% (all p < .0001). Decreased transfusion with luspatercept in patients with TDT was associated with increased erythropoietic markers and decreasing hepcidin. Furthermore, s-ferritin reduction associated with increased erythroid iron incorporation (marked by sTfR1) allowed increased erythrocyte marrow output, consequently reducing transfusion needs and enhancing rerouting of hemolysis (heme) iron and non-transferrin-bound iron to the liver. LIC increased in patients with intact spleens, consistent with iron redistribution given the hepcidin reduction. Thus, erythropoietic and hepcidin changes with luspatercept in TDT lower transfusion dependency and may redistribute iron from macrophages to hepatocytes, necessitating the use of concomitant chelator cover for effective iron management.
引用
- Garbowski MW, Ugidos M, Risueño A, et al. Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia. Am J Hematol. 2023. PMID: 37782758. doi:10.1002/ajh.27102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。